Literature DB >> 1172254

Dopaminergic drugs antagonize the psychotomimetic effects of partial-agonist analgesics.

W R Buckett, J S Shaw.   

Abstract

The psychotomimetic actions of the partial-agonist analgesic drugs cyclazocine and levallophan have been demonstrated using a quantitative behavioural test in young rats which measures lateral head movements and pivoting on the hind paws. This drug induced behaviour is antagonized by low doses of the dopaminergic agonists apomorphine and piribedil, the dopamine releasing drug amphetamine, the dopamine reuptake blocking agent benztropine and by large doses of the dopamine precursor L-Dopa. Naloxone antagonize the behaviour, but only at one hundred times the analgesic antagonist dose. These results show that dopaminergic systems are implicated in the mechanism of action of partial-agonist induced psychotomimetic side effects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1172254     DOI: 10.1007/bf00421271

Source DB:  PubMed          Journal:  Psychopharmacologia


  4 in total

1.  Evidence for increased apomorphine-sensitive dopaminergic effects after acute treatment with morphine.

Authors:  J Scheel-Krüger; K Golembiowska; E Mogilnicka
Journal:  Psychopharmacology (Berl)       Date:  1977-06-06       Impact factor: 4.530

2.  Behavioral effects of cyclazocine on rats assessed in the open field and residential maze.

Authors:  R Looser; J Elsner; G Zbinden
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

3.  Effects of acute administration of cyclazocine on the metabolism of biogenic amines in different regions of rat brain.

Authors:  M M Gavend; F Serre; M R Gavend; C Ragoucy; P Caron
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

4.  Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine.

Authors:  G Curzon; J C Fernando; A J Lees
Journal:  Br J Pharmacol       Date:  1979-08       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.